Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 1.14 Billion AUD | -8.41% |
| 2023 | 1.24 Billion AUD | -3.09% |
| 2022 | 1.28 Billion AUD | -11.98% |
| 2021 | 1.46 Billion AUD | -19.83% |
| 2020 | 1.82 Billion AUD | 11.54% |
| 2019 | 1.63 Billion AUD | -10.61% |
| 2018 | 1.83 Billion AUD | -4.41% |
| 2017 | 1.91 Billion AUD | 22.96% |
| 2016 | 1.55 Billion AUD | 194.43% |
| 2015 | 528.94 Million AUD | 98.99% |
| 2014 | 265.82 Million AUD | 13.89% |
| 2013 | 233.39 Million AUD | 332.74% |
| 2012 | 53.93 Million AUD | 0.48% |
| 2011 | 53.67 Million AUD | -24.56% |
| 2010 | 71.14 Million AUD | 785.41% |
| 2009 | 8.03 Million AUD | -31.28% |
| 2008 | 11.69 Million AUD | -24.61% |
| 2007 | 15.51 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.14 Billion AUD | -0.91% |
| 2024 Q4 | 1.14 Billion AUD | 0.0% |
| 2024 Q2 | 1.15 Billion AUD | 0.09% |
| 2024 FY | 1.14 Billion AUD | -8.4% |
| 2024 Q1 | 1.15 Billion AUD | -10.5% |
| 2023 Q2 | 1.49 Billion AUD | 0.01% |
| 2023 FY | 1.24 Billion AUD | -3.09% |
| 2023 Q1 | 1.49 Billion AUD | 14.62% |
| 2023 Q4 | 1.28 Billion AUD | 3.25% |
| 2023 Q3 | 1.24 Billion AUD | -16.49% |
| 2022 Q2 | 1.48 Billion AUD | 0.99% |
| 2022 Q4 | 1.3 Billion AUD | 1.18% |
| 2022 FY | 1.28 Billion AUD | -11.98% |
| 2022 Q3 | 1.28 Billion AUD | -13.12% |
| 2022 Q1 | 1.46 Billion AUD | 0.32% |
| 2021 Q1 | 1.48 Billion AUD | -18.53% |
| 2021 FY | 1.46 Billion AUD | -19.83% |
| 2021 Q2 | 1.5 Billion AUD | 0.97% |
| 2021 Q4 | 1.46 Billion AUD | 0.0% |
| 2021 Q3 | 1.46 Billion AUD | -2.54% |
| 2020 Q4 | 1.82 Billion AUD | 0.0% |
| 2020 FY | 1.82 Billion AUD | 11.54% |
| 2020 Q2 | 1.88 Billion AUD | 0.97% |
| 2020 Q3 | 1.82 Billion AUD | -3.28% |
| 2020 Q1 | 1.86 Billion AUD | 14.22% |
| 2019 Q4 | 1.63 Billion AUD | 0.04% |
| 2019 FY | 1.63 Billion AUD | -10.61% |
| 2019 Q3 | 1.63 Billion AUD | -18.72% |
| 2019 Q1 | 2.01 Billion AUD | 9.94% |
| 2019 Q2 | 2.01 Billion AUD | 0.0% |
| 2018 Q4 | 1.83 Billion AUD | -0.0% |
| 2018 Q2 | 1.72 Billion AUD | 0.0% |
| 2018 FY | 1.83 Billion AUD | -4.41% |
| 2018 Q1 | 1.72 Billion AUD | -9.66% |
| 2018 Q3 | 1.83 Billion AUD | 5.81% |
| 2017 Q3 | 1.9 Billion AUD | -2.05% |
| 2017 Q2 | 1.94 Billion AUD | 0.0% |
| 2017 Q4 | 1.91 Billion AUD | 0.36% |
| 2017 Q1 | 1.94 Billion AUD | 25.08% |
| 2017 FY | 1.91 Billion AUD | 22.96% |
| 2016 FY | 1.55 Billion AUD | 194.43% |
| 2016 Q1 | 601.21 Million AUD | 13.66% |
| 2016 Q4 | 1.55 Billion AUD | 2.07% |
| 2016 Q3 | 1.52 Billion AUD | 153.79% |
| 2016 Q2 | 601.21 Million AUD | 0.0% |
| 2015 Q3 | 528.94 Million AUD | 65.33% |
| 2015 Q2 | 319.94 Million AUD | 0.0% |
| 2015 FY | 528.94 Million AUD | 98.99% |
| 2015 Q4 | 528.94 Million AUD | 0.0% |
| 2015 Q1 | 319.94 Million AUD | 20.36% |
| 2014 FY | 265.82 Million AUD | 13.89% |
| 2014 Q2 | 256.62 Million AUD | 0.0% |
| 2014 Q3 | 265.82 Million AUD | 3.58% |
| 2014 Q4 | 265.82 Million AUD | 0.0% |
| 2014 Q1 | 256.62 Million AUD | 9.95% |
| 2013 FY | 233.39 Million AUD | 332.74% |
| 2013 Q3 | 233.39 Million AUD | 0.0% |
| 2013 Q4 | 233.39 Million AUD | 0.0% |
| 2012 Q4 | 53.93 Million AUD | 0.0% |
| 2012 FY | 53.93 Million AUD | 0.48% |
| 2011 FY | 53.67 Million AUD | -24.56% |
| 2011 Q4 | 53.67 Million AUD | 0.0% |
| 2010 Q4 | 71.14 Million AUD | 0.0% |
| 2010 FY | 71.14 Million AUD | 785.41% |
| 2009 Q4 | 8.03 Million AUD | 0.0% |
| 2009 FY | 8.03 Million AUD | -31.28% |
| 2008 FY | 11.69 Million AUD | -24.61% |
| 2008 Q4 | 11.69 Million AUD | 0.0% |
| 2007 FY | 15.51 Million AUD | 0.0% |
| 2007 Q4 | 15.51 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AstraZeneca PLC | 100.97 Billion USD | 98.868% |
| Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 98.799% |
| CSPC Pharmaceutical Group Limited | 6.52 Billion USD | 82.477% |
| Clarus Therapeutics Holdings, Inc. | 51.7 Million USD | -2110.832% |
| Novartis AG | 99.94 Billion USD | 98.856% |
| PT Kalbe Farma Tbk. | 1.75 Billion USD | 35.0% |